Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 3/20 | 0.58 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177978 | 1.00 | ERBB2 (0.58) | ERBB2MINK1ADRB2CA9TYR | |
| SCHEMBL5187361 | 0.96 | ERBB2 (0.59) | ERBB2MINK1ADRB2CA9TYR | |
| SCHEMBL5187373 | 0.96 | ERBB2 (0.59) | ERBB2MINK1ADRB2CA9TYR | |
| SCHEMBL5186776 | 0.91 | ERBB2 (0.54) | ERBB2MINK1GLS | |
| SCHEMBL5186768 | 0.91 | ERBB2 (0.54) | ERBB2MINK1GLS | |
| SCHEMBL5187543 | 0.90 | ERBB2 (0.54) | ERBB2MINK1GLS | |
| SCHEMBL5187534 | 0.90 | ERBB2 (0.54) | ERBB2MINK1GLS | |
| SCHEMBL5187813 | 0.89 | ERBB2 (0.54) | ERBB2MINK1CA9ABL1BCR | |
| SCHEMBL5187823 | 0.89 | ERBB2 (0.54) | ERBB2MINK1CA9ABL1BCR | |
| SCHEMBL5186734 | 0.89 | ERBB2 (0.59) | ERBB2MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794155-A1 | OXAZOLE DERIVATIVES AS HER TYROSINE KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-20060069095-A1 | Azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | US | disclosed |
| WO-2006032520-A1 | OXAZOLE DERIVATIVES AS HER TYROSINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069095-A1 | Azole derivatives | CYP3A5, CYP3A43, CYP11B1 | ERBB2 2139/4885MINK1 2091/4885ADRB2 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.